Gemcabene: Phase IIb started

Gemphire began the open-label, international Phase IIb COBALT-1 trial to evaluate once-daily oral gemcabene for 12 weeks in 8 patients with HoFH on lipid-lowering therapy. Patients will receive 300 mg...